DelveInsight’s, “Psoriasis Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including Psoriasis clinical trials and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Psoriasis clinical trials studies, Psoriasis NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Psoriasis Pipeline Insight Report
- Over 80+ Psoriasiscompanies are evaluating 80+ Psoriasispipeline therapies in various stages of development, and their anticipated acceptance in the Psoriasismarket would significantly increase market revenue.
- The leading Psoriasis Companies includes Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
- Promising Psoriasis Pipeline Therapies includes Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, LAS41004, Calcipotriene Foam, Talarozole, U0267, and others.
- The Psoriasis companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The Psoriasis pipeline therapies under development are focused on novel approaches to treat/improve Psoriasis.
To explore more information on the latest breakthroughs in the Psoriasis Pipeline treatment landscape of the report, click here @ Psoriasis Pipeline Outlook
Psoriasis Overview
Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis. It is possible to observe mild (<2%), moderate (2–10%), and severe (>10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions. Topical therapies are the standard of care for the treatment of mild to moderate form of the disease.
Latest Breakthroughs or News of the Psoriasis Treatment Landscape
- In November 2020, Biohaven Pharmaceutical collaborates with Weill Cornell Medicine, to initiate a clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis. CGRP is a neuropeptide and believed to play an important role in the pathogenesis of inflammatory skin diseases such as psoriasis.
For further information, refer to the detailed Psoriasis Unmet Needs, Psoriasis Market Drivers, and Psoriasis Market Barriers, click here for Psoriasis Ongoing Clinical Trial Analysis
Psoriasis Emerging Drugs Profile
- Topical roflumilast: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.
- GSK2982772: GlaxoSmithKline
GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.
Psoriasis Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.
Request a sample and discover the recent advances in Psoriasis Ongoing Clinical Trial Analysis and Medications, click here @ Psoriasis Treatment Landscape
Scope of the Psoriasis Pipeline Insight Report
- Coverage- Global
- Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
- Psoriasis Pipeline Therapies- Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, LAS41004, Calcipotriene Foam, Talarozole, U0267, and others.
- Psoriasis Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for drugs for Psoriasis Market Drivers and Psoriasis Market Barriers, click here @ Psoriasis Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Psoriasis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Psoriasis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Psoriasis Collaboration Deals
- Late Stage Products (Phase III)
- CT-P43: Celltrion
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- EDP1815: Evelo Biosciences
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AZD0284: AstraZeneca
- Drug profiles in the detailed report…..
- Early Stage Products (Preclinical)
- AZD0284: AstraZeneca
- Drug profiles in the detailed report…..
- Inactive Products
- Psoriasis Key Companies
- Psoriasis Key Products
- Psoriasis- Unmet Needs
- Psoriasis- Market Drivers and Barriers
- Psoriasis- Future Perspectives and Conclusion
- Psoriasis Analyst Views
- Psoriasis Key Companies
- Appendix
Got Queries? Find out the related information on Psoriasis Mergers and acquisitions, Psoriasis Licensing Activities @ Psoriasis Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services